Cas:6487-91-8 2-(3-methylphenyl)ethanethioamide manufacturer & supplier

Chemical Name:2-(3-methylphenyl)ethanethioamide

CAS.NO:6487-91-8

Synonyms:m-tolyl-thioacetic acid amide;2-(2-AMINOETHYLAMINO)ETHANOL-D4;m-Tolyl-thioessigsaeure-amid;2-m-tolyl-thioacetamide;m-Tolylthioacetamid;Benzeneethanethioamide,3-methyl;3-methylphenyl(thioacetamide);2-(3-methylphenyl)-ethanethioamide

Molecular Formula:C₉H₁₁NS

Molecular Weight:165.25500

HS Code:2930909090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:294.1ºC at 760 mmHg

Density:1.122g/cm3

Index of Refraction:1.616

PSA:58.11000

Exact Mass:165.06100

LogP:2.52390

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like m-tolyl-thioacetic acid amide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(3-methylphenyl)-ethanethioamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(3-methylphenyl)-ethanethioamide Use and application,2-(2-AMINOETHYLAMINO)ETHANOL-D4 technical grade,usp/ep/jp grade.

Related News: The CDC’s delay likely came as a disappointment to representatives for the immunocompromised community, who pleaded with the CDC’s expert group to give the go-ahead for booster use in these people, who do not mount a strong enough defense against the virus. p-(N-Propyl-N-2-propenylsulfamoyl)benzoesaeure manufacturers A thorough safety and risk analysis procedure should be administered at an appropriate time with documentation that adheres to the rules and regulations set forth by the regulatory authorities. 1-(diethylamino)-3-(2,6-dimethylphenyl)propan-2-ol suppliers An inherent advantage of using enzymes for synthetic chemistry is that they increase regio-, enantio-, and stereoselectivity for more efficient conversion of substrate to product. methyl 4-[(4-chloromethyl-1H-imidazol-1-yl)ethyl]benzoate vendor & factory The CDC’s delay likely came as a disappointment to representatives for the immunocompromised community, who pleaded with the CDC’s expert group to give the go-ahead for booster use in these people, who do not mount a strong enough defense against the virus.,The suit says that while BRAF kinase inhibitors existed prior to Plexxikon’s discoveries, they were not selective, and Plexxikon’s have a core molecular structure that allows them to bind selectively to kinase created by the BRAF mutation. That allows for higher doses to be administered.